在患有下肢动脉疾病的患者中Ezetimibe Plus 类药物的临床结果

相关实验视频

Updated: Sep 10, 2025

09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Yoshihiro Iwasaki¹, Takenobu Shimada², Takefumi Kishimori¹

¹Department of Cardiovascular Medicine, Omi Medical Center, Kusatsu, Japan.

JACC. Advances

|August 19, 2025

概括

强化降脂治疗以ezetimibe加上他类药物显著减少主要不良四肢事件和死亡率在患有下肢动脉疾病 (LEAD) 的患者. 这种组合疗法为改善LEAD患者的治疗结果提供了一个有希望的策略.

科学领域:

心血管医学心血管医学
药理学药理学是指药理学的学科.
公共卫生公共卫生

背景情况:

对于冠状动脉疾病,已知有Ezetimibe加他类药物治疗的好处,但对于下肢动脉疾病 (LEAD) 则没有.
LEAD患者面临重大不良肢体事件和死亡的重大风险.

研究的目的:

评估以泽提米布加他类药物与他类药物单一治疗在减少LEAD患者主要不良肢体事件和死亡率方面的疗效.
评估强化降脂策略对肢体救援和LEAD整体存活率的影响.

主要方法:

从TrinetX数据库 (2013-2022) 中对LEAD患者 (≥18岁) 的回顾性分析.
排除最近患有急性冠状动脉综合征或中风的患者.
倾向性得分匹配创建了可比较的组 (每组4204名患者) 来分析12个月主要下肢截肢和全因死亡的复合终点.

主要成果:

较大的下肢截肢和全因死亡的复合终点与单独治疗的他类药物相比,以泽提米布加他类药物显著较低 (5.8%对10.2%;HR:0.54).
两种主要的下肢截肢 (2.7%对4.6%) 和全因死亡 (3.4%对6.3%) 都在组合治疗下单独减少.
在所有子组分析中都观察到一致的好处.

结论:

使用ezetimibe加上他类药物的强化降脂策略显著减少了现实世界LEAD患者的主要下肢截肢和全因死亡率.
与单独使用他类药物相比,这种组合治疗是一种优越的方法,用于管理脂质配置文件并改善LEAD的临床结果.

关键词:

领先的领导力所有原因的死亡率.埃塞蒂米贝贝是什么意思主要的下肢截肢是截肢.斯塔丁斯塔丁斯是一个国家.

相关概念视频

01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

869

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

869

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...

01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...